Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 4Phase 3 3Phase 1/2 3Phase 2/3 1

Status

Completed 3Unknown 2Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 1Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × folfirinox × Clear all
NCT03941093 2024-11-05

LAPIS

Kyntra Bio

Phase 3 Completed
284 enrolled 14 charts
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT01827553 2024-04-11

CONKO-007

University of Erlangen-Nürnberg Medical School

Phase 3 Completed
830 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Cornerstone Pharmaceuticals

Phase 3 Completed
528 enrolled 11 charts
Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡